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Pediatrics is the branch of medicine that deals 
with the care of infants, children and adolescents. 
The age limit is newborn till 21 years. Islamic 
writers such as Ibn Sina have contributed to Greco-
Roman and Byzantine medicine. The Persian 
scholar and doctor Al-Razi published a thesis on 
diseases in children. Neonates, infants and children 
differ markedly from adults, physiologically. 
Developmental delays, genetic mutations and 
congenital defects are of greater concern to 
pediatricians as compared to physicians practicing 
adult medicine.
Moving a step further, pediatric pathologist is more 
of a generalist then a specialist. This field covers a 
wide spectrum of abnormalities occurring during 
From the Editor’s Desk
development, extending through childhood and 
culminating in adolescence. 
This is the first time that an issue of LABRAD 
has been exclusively dedicated to pathologies of 
the pediatric population. We have covered topics 
related to inherited bleeding disorders, endocrine 
abnormalities, malignant diseases and genetic 
disorders to name a few.
This year’s last issue ends on a “thematic” note. 
Hope our readers will be enlightened as always. We 
will continue to publish thematic issues like these in 
the years to come.
Natasha Ali
Inherited bleeding disorders may be due to a vascular 
defect, a platelet disorder or a coagulation defect. 
Table 1 shows the causes of inherited bleeding 
disorders based on this classification:
Approaching a child with bleeding disorder mainly 
consists of the following:
1. History taking
2. Clinical Examination 
3. Laboratory Findings
Overview on Approach to Inherited Bleeding 
Disorders
Dr Nadia Nasir
Haematology
Type of Bleeding 
Disorder
Vascular Defect
Platelet Defect
Coagulation 
Defect
Common Inherited 
Bleeding Disorders
1. Hereditary Hemorrhagic Telengiectasia
2. Ehlers Danlos Syndrome
3. Henoch-Schonlein Purpura
1. Glanzmann Thrombasthenia
2. Bournard Soulier Syndrome
1. Haemophillia A (Factor Viii Deficiency)
2. Haemophillia  (Factor Ix Deficiency
3. Afibrinogenaemia/Dysfibrinogenaemia
Table 1: The Causes of Inherited Bleeding Disorder
Inherited bleeding disorders compared to acquired 
bleeding disorders, tend to have an early age 
of presentation, where bleeding is a dominant 
feature and usually with a positive family history. 
The pattern of bleeding is relatively predictable 
depending on the etiology. Vascular and platelet 
disorders tend to be associated with bleeding from 
the mucous membrane and into the skin, whereas in 
coagulation disorders the bleeding is often into joints 
or soft tissue as shown in Table 2.
An appropriate and reliable laboratory approach, 
encompassing first-line (screening) and second-
Table 2: Adapted from Essential Haematology
Mucosal Bleeding
Petechiae
Deep Haematomas
Bleeding From Cuts
Gender
Platelet/Vessel 
Wall Diseases
Common
Common
Rare
Persistent
Equal
Coagulation 
Diseases
Rare
Rare
Common
Minimal
Mostly Males
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should be performed as demonstrated in the above 
figure.
Assays for Evaluation of Coagulation Factor 
Function
The prothrombin time (PT) and 
activated PTT are coagulation 
screening tests performed on 
citrated plasma. The PT is 
reported commonly along with the 
International Normalized Ratio 
(INR) to adjust for different reagent 
sensitivities. The PT is a measure 
of the extrinsic (FVII) and common 
pathway (FV, FX, prothrombin, 
fibrinogen) clotting factors. The 
PTT measures the contact system 
(prekallikrein, FXII) as well as the 
intrinsic (FVIII, FIX, FXI) and 
common pathway clotting factors. 
Sensitivities of various PT and PTT 
reagents vary and may yield normal 
values in the presence of mild factor 
deficiencies. Therefore, specific 
factor assays should be performed 
for patients who are strongly 
suspected of having a bleeding 
disorder. Table 3 shows interpretation of laboratory 
results for common inherited bleeding disorder.
line (specific) testing, is essential to screen, 
diagnose, and monitor patients who have 
bleeding diatheses Figure 1. The available 
clinical assays also can be grouped according to 
whether they evaluate components of primary 
hemostasis or coagulation factors.
Assays for Evaluating Primary Hemostasis
A complete blood count and evaluation of the 
peripheral blood smear usually constitute 
the required first step. The bleeding time 
is the historical screening test for defects 
of primary hemostasis, but low sensitivity 
and specificity in children limit its utility. 
Newer platelet function analyzers (PFAs) 
are now available in clinical laboratories but 
cannot be relied on to identify all patients 
who have von Willibrand disease or platelet 
function defects, and their routine use 
remains controversial. Therefore, when these 
disorders are considered, specific testing 
(vWF indices, platelet aggregation studies) 
Figure 1: adapted from pedsinreview aappublications
Table 3: Adapted from essential haematology
Factor VII
Normal 
Normal
Normal
Prolonged
Pt Aptt Corrected 
By Normal Plasma 
Vii Deficiency
Factor IX
Normal 
Normal
Normal 
Prolonged
Pt Aptt Corrected 
By Normal Plasma
Ix Deficiency
VWB
Normal 
Increased
Normal 
Prolonged
Pt Aptt Corrected 
By Normal Plasma
Vwb Deficiency
Complete 
Blood Counts
Bleeding Time 
PT
APTT
Mixing 
Studies
Factor Assays
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Haemoglobinopathies refer to a diverse group 
of inherited disorders characterized by a 
reduced synthesis of one or more globin chains 
(thalassaemias) or the synthesis of structurally 
abnormal haemoglobin. They encompass a 
heterogeneous group of disorders associated with 
mutations in both the alpha-globin and beta-globin 
genes.
Diagnosis of haemoglobinopathies, including 
thalassaemias, can result from either a clinical 
suspicion of a disorder of globin chain synthesis or 
from follow-up of an abnormality detected during 
screening. Screening may be carried out as part of 
a well-defined screening program or be an ad hoc 
or opportunistic test. 
Step wise approach to Diagnosis
Complete Blood Count
Structural haemoglobinopathies may have 
an impact on the red cell indices, which are 
critical to the diagnosis of thalassaemias. The 
key components of the CBC include: Hb, red 
cell count, mean corpuscular volume (MCV), 
and red cell distribution width (RDW). The 
thalassaemias generally are classified as 
hypochromic and microcytic anemias. Hence the 
MCV is a key diagnostic indicator and reported 
in femtoliters, in most adult populations ranges 
from ~80 to 100 fL. Thalassaemic individuals 
have a reduced MCV, and studies suggest that 
an MCV of 72 fL is maximally sensitive and 
specific for presumptive diagnosis of thalassemia 
syndromes. RDW may provide information 
useful as an adjunct to diagnosis but is not 
useful as alone indicator. The RBC count is 
also useful as a diagnostic adjunct because the 
thalassemias produce a microcytic anemia with 
an associated increase in the RBC number. 
Various indices utilizing these CBC components 
have been developed with a view to providing a 
mathematical derivation to reliably differentiate 
iron deficiency from thalassemia minor. None are 
useful in all clinical settings, and probably none 
exceed the value of the MCV alone in selecting 
cases for subsequent investigations.
Hb H Inclusion
Hb H refers to an insoluble Hb tetramer comprising 
four β-globin chains. Hb H arises in the setting of 
α-thalassemia where the decreased production of 
α-globin chains leads to β-globin excess. Oxidation 
of these tetramers provokes precipitation, which can 
be visualized microscopically. But the Hb H stain 
is nonspecific in that other nucleic acid or protein 
precipitates also stain. 
In the setting of Hb H disease, a disorder in 
which three of four α-globin chain genes are not 
expressed, 30–100 per cent of red cells contain 
typical inclusions. In contrast, α-thalassemia 
minor may be associated with as few as one 
inclusion-containing cell in 1000–10 000 cells. 
The absence of Hb H inclusions therefore does 
not exclude thalassemia trait, but the presence of 
typical inclusions may be helpful in confirming a 
presumptive diagnosis.
Electrophoresis
Traditionally, electrophoresis has been the method 
of choice for identification and quantification of 
variant Hbs. Commercial, rapid electrophoretic 
methods have been developed that allow for 
separation at pH 8.4 (alkaline) and pH 6.2 (acid) on 
agarose gels. 
However, it is slow, labor-intensive, and inaccurate 
in the quantification of low-concentration Hb 
variants (e.g., Hb A2) or in the detection of fast Hb 
variants (Hb H, Hb Barts).
Isoelectric Focusing
IEF is an electrophoretic technique with 
excellent resolution. Although labor-intensive 
and time-consuming, it has been used to 
identify and quantify Hbs. IEF is an equilibrium 
process in which Hb migrates in a pH gradient 
to a position of zero net charge. The narrow 
bands obtained on IEF allow for more precise 
and accurate quantification than standard 
electrophoresis.
Diagnostic Approach to Haemoglobinopathies
Dr Sidra Asad Ali and Dr Anila Rashid
Haematology
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Capillary Isoelectric Focusing
It is a hybrid technique combining the capillary 
electrophoresis sensitivity of detection with the 
automated sampling and data acquisition of HPLC. 
Many published works have described the utility 
of CIEF in the detection and quantification of Hb 
variants. Separation of the Hb in this method is 
related to the isoelectric point of the Hb, and this 
may enhance inter-laboratory reproducibility.
High Performance Liquid Chromatography
Cation-exchange HPLC is emerging as the method 
of choice for the initial screening of Hb variants 
(including neonatal screening where this is 
mandated) and for quantification of Hb A2 and Hb 
F concentrations. The Bio-Rad Variant (Bio-Rad 
Laboratories) is an automated cation-exchange 
HPLC instrument that has been used to quantify 
Hb A2, Hb F, Hb A, Hb S, and Hb C. College 
of American Pathologists studies have shown 
equivalence or superiority over electrophoretic 
methods. In comparison with haemoglobin 
electrophoresis, HPLC has the following advantages:
1.  The analysers are automated, therefore require 
 less staff time and permit processing of large 
 batches.
2.  Very small sample volumes (5 μL) are sufficient 
 for analysis.
3.  Quantification of normal and separated variant 
 haemoglobins is available on every sample.
4.  Provisional identification of a larger proportion 
 of variant haemoglobins can be made.
5.  δ chain variants (recognition of which is 
 important in the diagnosis of β thalassaemia 
 heterozygosity) are more easily detected. 
DNA Analysis
After presumptive identification of 
hemoglobinopathies and thalassemia syndromes, 
and particularly for purposes of genetic counseling, 
defining the mutation or deletion present may 
be required. Typically, deletional mutations 
causing α-thalassemia syndromes and some rare 
β-thalassemias are diagnosed using Southern blot 
hybridization of particular restriction enzyme 
digests to labeled complementary gene probes. 
PCR techniques using allele-specific probes after 
globin gene amplification, allele-specific primers, 
or deletion-dependent amplification with flanking 
primers are used in definition of known globin chain 
mutations/deletions. For unknown mutations, several 
PCR-based methods, including denaturing gradient 
gel electrophoresis and single-strand conformation 
polymorphism analysis, as well as sequencing of the 
amplified globin gene DNA may be used.
With increasing global awareness and mass 
screening programs undertaken at various levels by 
health care system, the responsibility for laboratory 
personnel has greatly enhanced in detection and 
prevention of haemoglobinopathies. Detection of 
asymptomatic carriers by reliable laboratory methods 
is the cornerstone of prevention of this serious health 
problem. Awareness about the diagnostic problems as 
well as their solutions is also very important so that 
one does not miss a single case. 
Biochemical work up of  Nephrotic Syndrome 
in Paediatrics Population
Dr Khushbakht Arbab
Chemical Pathology
Childhood nephrotic syndrome can start at any age, 
but usually begins between the ages of two and 
five years. It is a rare condition that affects about 
16 out of every 100,000 children at any given time, 
and it affects more boys than girls. It is extremely 
unlikely that other children in a family will also 
have nephrotic syndrome. While there are a few 
types of nephrotic syndrome which do run in 
families, these are very rare. Nephrotic syndrome, or 
nephrosis, is defined by the presence of nephrotic-
range proteinuria, edema, hyperlipidemia, and 
hypoalbuminemia. 
Along with obtaining a complete medical history, 
a series of biochemical tests are required in order 
to arrive at an accurate diagnosis that verifies the 
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 presence of the illness. In addition, imaging of the 
kidneys (for structure and presence of two kidneys) 
is sometimes carried out, and/or a biopsy of the 
kidneys. Laboratory evaluation of patients suspected 
of nephrotic syndrome may include the following:
Urinalysis 
Microscopic hematuria is present in 20 per cent of 
cases of nephrotic syndrome but cannot be used 
to distinguish between minimal change nephrotic 
syndrome and other forms of glomerular disease. 
Red blood cell casts, if present, are suggestive of 
acute glomerulonephritis, such as post infectious 
nephritis, or a nephritic presentation of chronic 
glomerulonephritis, such as membranoproliferative 
glomerulonephritis. Furthermore granular casts may 
be present and are non-specific to etiology.  
Urine Protein Quantification
In children it is defined as protein excretion of 
more than >3.5 g per 1.73 m2 per 24 hours or a 
first-morning urine protein/creatinine of 2-3 mg/mg 
creatinine or greater.
Serum Albumin 
Serum albumin levels in nephrotic syndrome are 
generally less than 2.5 g/dL, however values as low 
as 0.5 g/dL are not uncommon due to renal albumin loss.
Lipid Panel 
Heavy proteinuria leading to hypoalbuminemia 
causes compensatory increase in lipoprotein 
synthesis. This results in hyper lipoproteinemia. 
Elevated total cholesterol, low-density lipoprotein –
cholesterol and triglycerides may be noted.
Serum Electrophoretic 
Patterns in nephrotic syndrome show decreased 
albumin, and increased alpha 2-macroglobulin 
fraction.
Other Tests
Serum creatinine levels are usually normal unless the 
disorder has progressed to chronic kidney disease. 
Complete blood count,  serum electrolytes, and 
serum creatinine may also be tested. To evaluate 
the etiology of nephrotic syndrome, antibodies to 
HIV, hepatitis B and C, complement studies and  
antinuclear antibody and anti–double-stranded DNA 
antibody (in selected patients) may also be done.
The prognosis for nephrotic syndrome under 
treatment is generally good although this depends on 
the underlying cause, the age of the patient and their 
response to treatment. It is usually good in children, 
because minimal change disease responds very well to 
steroids and does not cause chronic kidney disease.
Transient Abnormal Myelopoiesis 
Dr Hira Qadir
Haematology
Introduction
Transient Abnormal Myelopoiesis (TAM) 
is a unique disorder of Down syndrome (DS) 
newborns that presents with clinical and 
morphologic findings indistinguishable from 
acute myeloid leukemia (AML). Hematologic 
abnormalities affecting red blood cells, white 
blood cells, and platelets are common in DS, 
particularly during childhood. Population-based 
studies show that risk for  leukemia is 10-20 
times higher in individuals with DS compared 
with the overall  population, with a particularly 
striking increase of the incidence of acute 
myeloid leukemia in young children with DS 
(approximately 150-fold).
Incidence
Data regarding the incidence of TAM in DS vary 
depending on the screening  practices and diagnostic 
criteria used. Reported incidence rate among infants 
with DS range from 10 - 30 per cent.
Disease Mechanism
TMD arises during fetal development and 
hematopoiesis. In the setting of trisomy 21, 
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megakaryocyte-erythroid progenitors (MEPs) 
are expanded during hematopoiesis in the fetal 
liver. Development of TAM appears to require the 
acquisition of a somatic mutation of the gene coding 
for the hematopoietic transcription factor GATA-1. 
GATA-1 mutations in TAM result in the expression 
of an amino-terminally truncated GATA1 protein 
(GATA1s). The functional consequence is impaired 
megakaryocytic differentiation and uncontrolled 
proliferation of a population of TAM  blasts as 
shown in Figure 1.
Clinical Presentation
 
Most patients are diagnosed within the first weeks 
of life. Some first come to clinical attention when 
circulating blasts are noted on a peripheral smear 
performed for screening purposes. Others are overtly 
ill with a wide range of physical and laboratory 
abnormalities at the time of diagnosis. Infiltration 
of solid organs with TAM is usually restricted to 
the liver, spleen, marrow, and skin.  Hepatomegaly 
(60 per cent) and splenomegaly (42 per cent) 
are commonly present at diagnosis of TAM. 
Lymphadenopathy is infrequent in TAM (two per 
cent of patients). At times, skin lesions consisting of 
papules, vesicles, and pustules may be the first sign 
pointing to TAM in a newborn with Down syndrome. 
On biopsy, these lesions may show infiltration by 
immature myeloid cells.
Laboratory Features
Peripheral smear and bone marrow:  TAM is 
characterized by the frequent presence of blasts 
(usually megakaryoblasts) in the peripheral blood 
Figure 2. Moderate leukocytosis is common 
(median white blood counts (28 to 40 x 109/L). 
Hemoglobin (median 14.6 to 14.8 g/L) and platelet 
count (median 96 to 125 x 109/L) are only mildly 
decreased. The flow cytometry immunophenotype 
of the non-lymphoid, non-erythroid blasts of TAM is 
characterized by the expression of megakaryoblastic 
/ megakaryocytic (CD61, CD41, CD42), stem cell 
(CD34, CD117), myeloid (CD13, CD33), and non-
lineage (CD4, CD7, CD56) antigens. Bone marrow 
examination demonstrates abnormal megakaryocytic 
maturation in 75 per cent and dyserythropoiesis in 25 
per cent.
Diagnostic Criteria
Diagnostic criteria for TAM are not universal. In 
most cases, the diagnosis is made based on the 
identification of blasts in the peripheral blood with a 
megakaryoblastic/megakaryocytic immunophenotype 
on flow cytometry. The most definitive test to identify 
TMD blasts is detection of a somatic mutation of 
GATA1, typically in exon two or three.
Figure 1: Disease Mechanism of TAM in Down Syndrome
Source: Xu G et al. Frequent mutations in the GATA-1 gene in the transient 
myeloproliferative disorder of Down syndrome. Blood 2003; 102:2960.
Figure 2: Blasts from the peripheral blood of 1-day-old with trisomy 21. 
Source: Pathology of Myeloid Proliferations Related to Down Syndrome. Author: 
Cherie H Dunphy, MD; Chief Editor Cherie H Dunphy
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Prognosis and Course 
TAM resolves spontaneously in the vast majority of 
patients. The two adverse outcomes of TAM are early 
death during the neonatal period and development 
of AML. TAM has an early mortality of up to 20 per 
cent and estimated five-year overall survival (OS) 
and event-free survival (EFS) rates of 85 and 63 
per cent, respectively. Approximately 20 per cent 
(13 to 30 per cent) of the patients with TAM go on 
to develop AML within the first four years of life. 
Due to this substantial risk for subsequent AML, all 
patients with a history of TAM are followed for signs 
and symptoms of progression.
Introduction of Maple Syrup Urine Disease 
(MSUD) Profile in Biochemical Genetics 
Laboratory at AKUH
Maple Syrup Urine Disease (MSUD) is an inherited  
amino acids metabolic disorder caused by a 
deficiency of the branched-chain alpha-keto acid 
dehydrogenase complex leading to a buildup of the 
branched chain amino acids (leucine, isoleucine, 
valine and alloisoleucine) and their toxic by-products 
(ketoacids) in the blood and urine. Clinically it can 
be classified as classic MSUD or other variants of 
MSUD.
Clinical Indications for MSUD Testing
l Maple syrup odor in urine, the first clinical sign of 
 MSUD, detectable 12 hours after birth.
l Poor feeding by age two to three days.
l Deepening encephalopathy including lethargy. 
l Intermittent apnea, opisthotonus, and stereotyped 
 movements (such as fencing and cycling) by age 
 four to five days.
l Coma and central respiratory failure that may 
 occur by age seven to ten days.
l Poor growth. 
l Irritability or developmental delays, later in 
 infancy or childhood. 
l Ketonuria and encephalopathy if stressed by 
 fasting, dehydration, or infectious illness.
Biochemical Characteristics of MSUD
Elevated plasma concentrations of branched-
chain amino acids (BCAAs) (leucine, isoleucine, 
and valine) and allo-isoleucine, accompanied 
by a more generalized disturbance of plasma 
amino acid concentration ratios, detectable 
by 12-24 hours of age in affected infants on a 
normal protein intake. Occasionally, plasma 
concentrations of isoleucine or valine may be low 
or normal, but plasma concentration of leucine is 
invariably elevated. Elevated plasma concentration 
of allo-isoleucine is specific and diagnostic for 
MSUD.
MSUD Profile at AKUH Clinical Laboratory
We have recently introduced MSUD profile at out 
biochemical genetics laboratory section of clinical 
chemistry. This profile includes:
l Leucine
l Isoleucine
l Valine
l Allo-isoleucine
As compared to our full plasma amino acid 
quantification, this shortened program allows 
the separation and quantification of the four 
branched chain amino acids. In addition to this, 
alloisoleucine is also identified in this profile 
unlike full plasma amino acid quantification. It is 
used as a specific and sensitive diagnostic marker. 
Quantitative amino acid analysis of these four 
branched-chain amino acids is crucial for the 
diagnosis and monitoring of MSUD.
Dr Noreen Sherazi and Dr Sheharbano Imran
Chemical Pathology 
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Urinary Tract Infections (UTI) in Children
Dr Fizza Farooqui
Microbiology
Urinary tract infections are a common cause of 
unexplained fever in infants and young children. 
Most guidelines suggest that fever of >38°C in this 
age group should raise suspicion of UTI, and thus, 
it is of utmost importance that they have their urine 
tested within 24 hours. 
Definitions
Guidelines proposed by National Institute of Health 
and Clinical Excellence (NICE) recommend that 
children be divided into three age groups; <3 months, 
three months to <3 years, and ≥3 years for the 
purpose of diagnosis. Children <3 months should 
have urgent microscopy of urine (>5 white blood 
cells/high power field) as well as cultures also from 
other sites (blood, cerebrospinal fluid if indicated) as 
they are at high risk of serious illness. For children 
three months to <3 years, urgent urine microscopy 
and culture is recommended, dipstick testing 
needs further discussion between microbiologists, 
pediatricians and primary care doctors. Dipstick 
testing is recommended for children >3 years, where 
a positive nitrite and leukocyte esterase denote 
infection. The American Academy of Pediatrics 
(AAP) recommends that diagnostic strategies depend 
on whether the clinician decides to start antimicrobial 
therapy or not. Diagnosis is dependent on the 
presence of pyuria and growth of ≥50,000 colony 
forming units of a single urinary pathogen from a 
urine specimen collected with a sterile technique. 
Samples
Collection of urine samples remains highly 
challenging in the younger age group. Clean 
catch urine specimens are recommended by NICE 
guidelines, samples collected in urine collection 
bags and pads have been reported to show equal 
rates of contamination. If none of these are possible, 
in/out catheters or ultrasound guided supra-pubic 
aspiration are the recommended methods of choice 
for collection. AAP recommends in/out catheters or 
supra pubic aspirates as the only methods of choice 
for urine collection.
Antibiotic Treatment 
Increase in antibiotic resistance, inconvenience, lack 
of compliance, and increased cost all add weight 
to the decision of discontinuation of antibiotic 
prophylaxis by the NICE guidelines. The AAP 
recommends that antibiotic treatment should start 
based on route of administration, local antibiogram, 
and subsequently upon susceptibility results from 
culture reports. The recommended duration of 
antibiotic therapy is 7-14 days. 
Preventive Measures
NICE guidelines advise that regular bladder 
emptying, general hygiene measures, drinking 
adequate amounts of fluids, breastfeeding and 
circumcision may prevent recurrence of UTI. 
AAP guidelines suggest that ultrasonography 
of the kidneys and bladder should be performed 
to detect structural abnormalities, and a voiding 
cystourethrogram obtained if there is evidence of 
hydronephrosis, scarring, or other complex clinical 
circumstances are encountered.
Thus, a high index of suspicion, appropriate 
sample collection and testing followed by regular 
follow up to prevent recurrent UTI remain 
the mainstay for management of urinary tract 
infections in children.
Key points:
Age Group
<3 months
3 months - <3 years
>3 years 
Microscopy
 √
√
√
Dipstick analysis (D/R)
 -
Debatable
 
√
Urine Culture (Clean catch/ suprapubic/ in/out catheters)
 √ (in addition to blood culture)
√
√
11
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Labrad Quiz
Dr Lena Jafri 
Chemical Pathology
A 6 year old girl was brought to a pediatrician for not 
being able to walk properly since one and a half year. 
Mother (Para +8) explained that her marriage was 
consanguineous and two of their boys (12 years and 
10 years old) had deformed bones and were unable to 
walk.. On examination, there are skeletal deformities 
of both upper and lower limbs, frontal bossing and 
pallor. Her extremities have widened wrists and ankles.
The laboratory and radiological evaluation included:
Serum Creatinine 0.5 mg/dl (0.5-1)
Serum Calcium 8.7 mg/dl (8.6-10.2)
Serum Phosphorus 1.8 mg/dl (2.5-4.5)
Alkaline phosphatase  1917 U/l (45-129)
25-hydroxy Vitamin D 32 ng/ml (>30)
Parathyroid hormone 90 pg/ml (16-87)
The pediatrician wanted to confirm his suspicion and 
ordered TMP-GFR in this patient.
Questions:
1. Which disease is the pediatrician suspecting?
2. Why did the pediatrician order TMP-GFR?
3. How is TMP-GFR calculated?
4. What is the pathophysiology of this disease?
5. Which other Vitamin D metabolite testing would  
 be helpful in establishing the diagnosis in this   
 patient?
An Overview of Congenital Adrenal Hyperplasia
Dr Sibtain Ahmad
Chemical Pathology 
Introduction
Congenital adrenal hyperplasia (CAH), an autosomal 
recessive inherited defects of enzymes involved in 
adrenal steroidogenesis due to mutations in specific 
genes. The common functional defect in each 
disorder is impaired cortisol secretion, resulting in 
hyper secretion of corticotrophin-releasing hormone 
(CRH) and adrenocorticotropic hormone (ACTH) 
and consequent hyperplasia of the adrenal glands. 
Those affected may present clinically as a classic 
(more severe) or nonclassic (less severe) type. 
About 75% of those with a classic deficiency will 
have a “salt-wasting” form that includes decreased 
aldosterone and leads to an excess loss of fluids, low 
sodium, and high potassium that, when severe, can 
be life-threatening. More than 90% of cases of CAH 
are caused by a defect in the enzyme 21-hydroxylase 
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(21OHD), which is caused by a mutation in the 
CYP21A2 gene. Four other enzyme deficiencies in 
the steroid biosynthesis pathway, along with one 
cholesterol transport protein defect, account for the 
remaining cases Figure 1. 
Signs and Symptoms of CAH
Signs and symptoms associated with 
CAH depend upon the type of enzyme 
deficiency and vary over time, less 
severe in non-classic diseases, getting 
worse in illness or stress to a life-
threatening adrenal crisis in classic 
type. 
Salt-wasting CAH signs and symptoms may 
include: Abnormal heart rhythm, rapid heart rate, 
confusion, dehydration, hyperkalemia, irritability, 
hypoglycemia, hypotension, hyponatraemia and 
vomiting. Females with classic 21OHD deficiency 
may have ambiguous external genitalia (external 
sex organs that are not clearly male or female 
with normal reproductive organs uterus, fallopian 
tubes, and ovaries) due to the diversion of pathway 
towards excess androgen production called as 
hyperandrogenism. Hyperandrogenism signs or 
symptoms in both males and females may include: 
accelerated skeletal growth (tall during childhood 
but short as adults), acne, deep voice, enlarged 
external genitalia, hirsutism in females, infertility, 
irregular menstruation , excess muscle growth or 
early development of pubic and armpit hair.
List of Tests available for Diagnosis of CAH at 
AKUH Laboratory
Diagnosis and differential diagnosis 
of CAH always requires the 
measurement of several steroids. 
Patients with CAH due to steroid 
21-hydroxylase defects/ deficiency 
usually have very high levels of 
androstenedione. Additionally 
17-OHP levels are usually even 
higher, while cortisol levels are low 
or undetectable Table 1. All three 
analytes should be tested when CAH 
is suspected. 
Patients with CAH due to steroid 
11 β-hydroxylase enzyme defects/
deficiency present with low 
levels of cortisol, aldosterone 
and renin. Whereas the levels of 
11-deoxycorticosterone (11-DOC) 
are elevated because deficiency of 
11 β-hydroxylase deficiency causes 
decreases conversion of 11-DOC to 
corticosterone and aldosterone.
The 17 α-OH enzyme deficiency is a rare variant 
of CAH and is characterized by hypertension 
in most cases. It presents with elevated levels 
of pregnenolone, progesterone, 11-DOC and 
corticosterone. However renin, aldosterone and 
cortisol levels are deficient.
The battery of tests performed of CAH diagnosis or 
monitoring are: 
1. Serum 17-hydroxyporgesterone (17OHP): 
 a. Screening: A 17-OHP test may be ordered 
   as a screening test of choice for newborn   
   screening to detect CAH due to 
   21-hydroxylase deficiency. The test may be  
Figure 1: Pathways of Steroid Biosynthesis in the Adrenal
Deficiency
21 β-OH
11 β-OH
17 α-OH
 Cortisol
↓
↓
↓
ACTH
↑
↑
↑
Blood Pressure
↓
↑
↑
Estrogen
-
-
↓
Androgen
↑ Adrenal
↑ Adrenal
↓ Adrenal & 
Testicular
Table 1: Biochemical Features in Different Forms of CAH
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    repeated if the screening result is elevated in 
   order to confirm the initial results. Table 2 
   shows the normal ranges of 17-OHP. 
 b. Diagnosis: Measurement of 17-OHP in the 
   blood may be used to aid in the diagnosis of 
   CAH in older children and adults who may 
   have a milder, “late-onset” form.
 c.  Monitoring: If someone is diagnosed with 
   CAH, a 17-OHP test may be used periodically 
   to monitor the effectiveness of treatment.
2. ACTH stimulation test:
Administration of 250 ug of cosyntropin (a synthetic 
ACTH) provides a pharmacologic stimulus to the 
adrenal glands, maximizing hormone secretion. 
The different forms of CAH due to 21OHD may 
be determined based on baseline and stimulated 
values of 17-OHP, the immediate precursor to the 
21-hydroxylase enzyme Table 2.
3.  Dehydroepiandrosterone Sulfate (DHEA-S):
CAH due to 3 beta-hydroxysteroid deficiency is 
associated with excessive DHEA-S production. 
Lesser elevations may be observed in 21-OHD 
deficiency and 11 β-OH deficiency. By contrast, 
steroidogenic acute regulatory protein or 17 alpha-
hydroxylase deficiencies are characterized by low 
DHEA-S levels.
4. Serum Testosterone: Approximately 10% 
of androstenedione is metabolized in the body to 
testosterone, a potent androgen. Consequently 
pronounced elevations are found in CAH.
5. Plasma Renin:  Elevated plasma renin activity 
values, particularly the ratio of renin to aldosterone, 
are markers of impaired mineralocorticoid synthesis.
6. Serum Electrolytes: especially sodium and 
potassium are routinely done in monitoring of CAH 
patients.
7. Plasma Glucose: is tested to evaluate for 
hypoglycemia. 
8. Additional tests: Karyotyping and pelvic and 
abdominal ultrasonography are further utilized 
diagnostic modalities. Kidney function and liver 
function tests may also be tested during management 
of these patients.
Burden of CAH in Pakistan
The true incidence of CAH in Pakistan remains 
unidentified due to the absence of new born 
screening program, lack of diagnostic testing 
facilities & disease awareness in the society and 
failure of case identification by primary physicians. 
A study from our center revealed that of the 152 
children registered for 17-hydroxyporegeterone 
(17-OHP) testing, sixty-three (41.4 per cent) were 
diagnosed with CAH. Among these salt wasting, 
simple virilization and non-classical CAH was found 
in 40 (63 per cent), 18(29.0 per cent) and 5 (8.0 
per cent) patients respectively. Another study from 
Pakistan showed variable frequency of referrals from 
different provinces of Pakistan. Higher frequency 
of cases with suspected CAH was observed from 
Sindh (23.7 per cent) as compared to other provinces. 
These studies show that CAH is not an uncommon 
disease, thus a well-structured and appropriate 
screening program of CAH is the need of time. 
Stage
Cord blood
Premature
Newborn-3days
Pre-pubertal child
Levels
<9.9 ng/mL
10- 100 ng/mL
>100 ng/mL
 Range (ng/mL)
9.0 - 50.0
0.26 - 5.68
0.07 - 0.77
0.03 - 0.90
Interpretation
Likely unaffected
Non-Classical congenital Adrenal Hyperplasia
Classic Congenital Adrenal Hyperplasia
Table 2: Normal ranges of 17Hydroxy Progesterone in Children 
of different age Groups
Table 2:  Interpretation of Results of 17OHP; 60 minutes after 
ACTH Stimulation
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Introduction
Paediatric renal tumours represent a relatively 
common group of childhood solid neoplasms. The 
diagnosis, management and prognosis of paediatric 
renal tumours have significantly improved over the 
last 40 years. Pathologists have played a significant 
role in these developments through their work in 
multicentre national and international trials and 
studies, by recognizing new tumour entities, as 
well as favourable and unfavourable histological 
features of different tumours. This review highlights 
salient clinical and pathologic features of common 
paediatric renal tumours.
Nephroblastoma (Wilms tumor)
Nephroblastomas comprise more than 80 per cent 
of renal tumours of childhood. Most often, they are 
found in children two to five years old, and they are 
relatively uncommon in the first six months of life 
and in children older than six years. Most patients 
come to medical attention because of a palpable 
abdominal mass. Other presentations may include 
abdominal pain, hematu¬ria, and hypertension.
Most (90 per cent) cases are sporadic; remainders are 
associated with one of the several syndromes, some 
of which are associated with abnormalities of the 
WT1 gene. Most are unilateral and unicentric, but 
bilateral tumours are present in five to 10 per cent 
cases, especially in familial cases. Those patients 
typically have a younger age at presen¬tation and are 
more prone to renal failure.
Nephroblastoma is derived from the nephrogenic 
blastemal cells and recapitulates various stages of 
the developing kidneys. Histologically, typically 
composed of variable mixtures of blastema, 
epithelium, and stroma (triphasic), although in some 
tumors only two (biphasic) or occasionally only one 
(monophasic) component is present. Most tumors 
have some degree of epithelial differentia¬tion 
manifested either as homologous (resembling normal 
nephrogenesis) or heterologous (mucinous and 
squamous) cell types. A variety of stromal patterns 
may be observed including immature myxoid and 
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spindled mesenchymal cells, smooth muscle, skeletal 
muscle, and neuroglial tissue.
For therapeutic and prognostic purposes, 
nephroblastomas are histologically divided into two 
major categories; those that are highly responsive 
to current therapeutic modalities are designated 
as nephroblastomas with favorable histology, and 
those that do not respond well to chemotherapy are 
relegated to the unfavorable histology group. The 
latter make up about five per cent of nephroblastomas 
and are defined by nuclear anaplasia. Anaplasia 
is rare in patients younger than two years but 
increases in incidence thereafter. Recognition of 
anaplasia requires the presence of markedly enlarged 
nuclei that are at least three-fold of non-anaplastic 
nuclei and hyperchromasia and atypical multipolar 
polyploid mitotic figures. Anaplasia may be diffuse 
or focal. It should be emphasized that anaplasia 
per se is not an indicator of the aggressiveness of a 
nephroblastoma but rather predictive of its resistance 
to adjuvant therapy.
Cystic Nephroma and Cystic Partially 
Differentiated Nephroblastoma
Cystic nephromas and cystic partially differentiated 
nephroblastomas (CPDNs) are tumours that are 
Figure: Nephroblastoma. 
Triphasic nephroblastoma contains blastemal, 
epithelial, and stromal elements
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currently believed to be a part of the spectrum of 
nephroblastoma. They present as solitary, well-
circumscribed lesions, consisting of numerous cysts 
of different sizes and shapes with no solid areas 
apart from the septa. The cysts are lined by flattened, 
cuboidal or hobnail epithelium, whereas the septa are 
composed of loose or dense fibrous tissue containing 
only mature elements (in cystic nephroma) or 
blastemal or other poorly differentiated cell types (in 
CPDN). Cystic nephromas/CPDNs are treated only 
by complete surgical resection, which is why it is so 
critical to distinguish them from other renal tumours 
that may have a prominent cystic appearance, such 
as clear cell sarcoma of kidney, rhabdoid tumor of 
kidney or nephroblastoma with cysts (particularly 
after preoperative chemotherapy), and which are all 
treated with postoperative chemotherapy.
Clear Cell Sarcoma of the Kidney
Clear cell sarcoma of the kidney (CCSK) is a rare 
malignant mesenchymal tumour representing three 
per cent of renal tumours of childhood. Its peak 
incidence is between two and three years of age, 
with a striking male predominance. Presentation is 
similar to other renal tumours, and around five per 
cent have metastatic disease at presentation, most 
commonly involving lymph nodes. Bone metastases 
are the most common mode of relapse, followed 
closely by lung metastases. Interestingly, in about 20 
per cent of cases relapses occur after >3 years, unlike 
in nephroblastoma, where >90 per cent of relapses 
occur within two years after the diagnosis.
Owing to its numerous patterns, CCSK remains 
the most frequently misdiagnosed renal tumour 
of childhood, especially on needle core biopsies 
specimens. Diagnosis is based on morphological 
criteria, since there is at present no diagnostic 
immunohistochemical or molecular test. 
Immunohistochemistry is primarily useful to exclude 
other renal tumours,
The classical pattern demonstrates nests ⁄cords of 
ovoid, epithelioid or spindled cells with bland nuclei 
separated by fibrovascular septa, which demonstrates 
a marked ‘chicken wire’ pattern of small blood 
vessels. About 90 per cent of tumours show at least 
some areas with the classical pattern, but other 
appearances are also reported, including myxoid (50 
per cent), sclerosing (35 per cent), cellular (26 per 
cent), epithelioid (13 per cent), pallisading (11 per 
cent), spindle-cell (seven per cent), storiform (four 
per cent), and anaplastic (three per cent) patterns.
The prognosis for CCSK has improved significantly 
since the introduction of doxorubicin to its treatment. 
The only significant histological factor associated 
with poor prognosis is the presence of necrosis. A 
favourable survival rate is associated with a lower 
tumour stage, an age of two to four years at diagnosis 
and treatment with doxorubicin. The overall survival 
is 69 per cent but this varies from 98 per cent for 
stage I to 50 per cent for stage 4 disease.
sheets and nests of tumor cells with pale vesicular 
nuclei are separated by thin vascular septa. Tumor 
cells are separated from each other by pale to clear 
extracel¬lular space that imparts a clear appearance.
Rhabdoid Tumour of Kidney
Rhabdoid tumour of kidney (RTK) is a distinctive, 
highly malignant paediatric renal tumour, usually 
metastasizes widely and causes the death of the 
Figure: Cystic partially differentiated nephroblastoma. 
The multilocular cysts are lined with flattened, 
cuboidal, or hobnail epithelium.
Figure: Clear Cell Sarcoma, 
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patient within 12 months of diagnosis. The tumour 
has a predilection for infants, with a median age of 
11 months; over 80 per cent of patients are under two 
years of age, and it virtually never occurs over five 
years of age.
Hema¬turia is the most common presentation, and 
hypercalcemia is a frequent finding. Reportedly, 15 
per cent of infants with rhabdoid tumor of the kidney 
have an associated PNET of the posterior fossa 
midline. Until recently, the definitive diagnosis could 
sometimes be difficult, but with the recent improved 
understanding of the genetic basis of the disease and 
the availability of specific immunohistochemical 
markers, the diagnosis can now be made with 
certainty, even on a needle biopsy specimen.
Characteristic histological features are the presence 
of large, non-cohesive tumour cells with eccentric 
large nuclei and very prominent eosinophilic central 
nucleoli, and focally hyaline intracytoplasmatic 
inclusions. Immunohistochemically, vimetin 
demonstrates characteristic strong dot-like 
perinuclear positivity in a significant proportion of 
cells and INI1 immunopositivity is characteristically 
absent in the nucleus of cells of rhabdoid tumour.
Congenital Mesoblastic Nephroma 
Congenital mesoblastic nephroma (CMN) is a low 
grade fibroblastic sarcoma of kidney comprises 
two per cent of all paediatric renal tumors. It is 
the most common congenital renal neoplasm, with 
more than 90 per cent of affected patients are less 
than one year of age, about two thirds are diagnosed 
in the first three months of life and virtually never 
occurring after the age of three years. Most patients 
present with a palpable abdominal mass, although 
an increasing number of tumours are detected 
sonographi¬cally in utero.
Histologically, CMN is categorized into two major 
histologic variants: the classic variant (22 per cent), 
which is composed of fascicles of bland fibroblastic 
cells with infrequent mitosis and resembles infantile 
fibromatosis; and the more common cellular variant 
(40-60 per cent), composed of solid sheets of ovoid 
cells with frequent mitosis and focal necrosis which 
is essentially identical to infan¬tile fibrosarcoma. 
A mixed pattern is recognized when features of 
both are present in a single tumor. Necrosis and 
hemorrhage are naturally more frequent in cellular 
variants. Tumour cells are usually positive with 
vimentin and focally for smooth muscle actin, 
although the diagnosis is based on morphological 
criteria alone. The cellular variant shares the same 
genetic abnormality as infantile fibrosarcoma: a 
t(12;15)(p13;q25) translocation with resultant ETV6-
NTRK3 fusion. The main factors of importance as 
risk factors for local recurrence are cellular subtype 
and incomplete local excision at primary surgery. 
They relapse within 12 months after the diagnosis, so 
during this period a close follow-up is recommended.
Figure: Rhabdoid Tumor of Kidney. 
Classic features include large nucleoli, abundant 
pink to amphophilic cytoplasm, and intracytoplasmic 
globules (arrows)
Figure: A. Classic form of Congenital Mesoblastic Nephroma. 
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Figure: Xp11 Translocation Carcinoma. 
Fibromatosis-like growth of well-differentiated 
spindle cells with entrapped glomerulus and tubules. 
B, Cellular congenital mesoblastic nephroma. 
High cell density, mitotically active spindle cell 
proliferation, also with entrapped glomeruli.
Renal Cell Carcinomas
Renal cell carcinomas (RCCs) represent around 
five per cent of all paediatric renal tumours, hence 
they are more common than CMN, CCSK or RTK. 
They show distinguishing histological and genetic 
features from RCCs seen in adults. These tumours 
are defined by several different translocations. A 
group of Xp11.2-translocation carcinomas resulting 
from fusion of the TFE3 gene is now recognized 
as a separate entity. Histologically, they show a 
typical nested appearance, but may also be papillary, 
composed of cells with granular eosinophilic 
cytoplasm or clear cells. Immunohistochemically, 
tumour cells show strong nuclear positivity for 
TFE3, which is diagnostic. A t(6;11)-translocation 
RCC is another translocation-associated paediatric 
RCC which has been rarely reported, and is seems 
to be less aggressive than Xp11.2-translocation 
RCC. Histologically, they feature nests and small 
acini of polygonal epithelioid cells with well-
defined cell borders, separated by a thin-capillary 
vasculature, but also another population of smaller 
epithelioid cells clustered around nodules of hyaline 
basement membrane material. A number of these 
tumours occur as post-chemotherapy tumours, 
including after neuroblastoma and nephroblastoma. 
Papillary carcinoma can also occur in older 
children. Carcinomas of the kidney need to be 
considered in children with von Hippel-Lindau 
disease and tuberous sclerosis. RCCs with lymph 
node metastases generally appear to have a better 
prognosis in children.
Large cells with eosinophilic cytoplasm and 
psammoma bodies with papillary and compact 
architecture.
Renal medullary carcinoma is a rare, highly 
aggressive tumour occurring in children and 
young adults with sickle cell trait or disease. 
Microscopically, it is very infiltrative, and is 
composed of large cells with large, vesicular nuclei 
and prominent nucleoli (rhabdoid features), usually 
accompanied by a marked acute and chronic 
inflammatory infiltrate and stromal desmoplasia. 
Interestingly, tumour cells may be negative for INI1 
marker. Patients usually present with widespread 
metastases and show no response to chemo- or 
radio-therapy, resulting in a poor survival (mean 4 
months).
Conclusion
Renal tumours of childhood are a fascinating group 
of tumours where huge progress in classification, 
treatment and understanding of molecular biology 
has been made. Since these tumours are rare, they 
still represent a diagnostic problem and central 
pathology review in multicentre trials is essential 
for assigning the appropriate treatment. Molecular 
biology markers are likely to play an even more 
important role in future trials.
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Introduction
Paediatric bone and soft tissue small round 
cell tumours (SRCTs) include Ewing sarcoma, 
rhabdomyosarcoma, poorly differentiated 
synovial sarcoma, lymphoblastic lymphoma, 
desmoplastic small round cell tumour, small cell 
osteosarcoma, mesenchymal chondrosarcoma, 
melanotic neuroectodermal tumour of infancy, and 
neuroblastoma. Accurate diagnosis is crucial as 
treatment modalities are different for each tumour. In 
this paper we will discuss salient features of each of 
these tumours and discuss role of histopathology in 
their diagnosis.
Ewing Sarcoma
Ewing sarcoma (ES) is a high grade sarcoma most 
often occur in children and young adolescents, with 
a male sex predilection. It commonly involves the 
diaphysis of long bones especially femur followed by 
sacrum and spinal column. Extraosseous ES is rare 
but increasingly recognized due to greater awareness 
of this tumor and better techniques of diagnosis. A 
typical ES is histologically characterized by sheets of 
uniform round cells with scant clear to eosinophilic 
cytoplasm, regular nuclear contours, finely dispersed 
chromatin and inconspicuous nucleoli. Mitotic 
activity is scarce and areas of geographic necrosis are 
frequently seen.  
A rare histologic variant of ES called atypical ES is 
characterized by sheets of large cells with irregular 
nuclei and prominent nucleoli, thus mimicking 
a large cell lymphoma. Despite their worrisome 
features, atypical ESs are similar to typical lesions in 
clinical behavior.
A high content of glycogen is seen in cells on 
periodic acid-Shiff (PAS) stain. Up to 99 per cent of 
ES show diffuse strong membranous expression of 
CD99. FLI-1 one is another sensitive marker positive 
in approximately 75 per cent cases of ES. In the 
appropriate clinical setting, morphology and diffuse 
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strong positivity of CD99 (and negative stains of 
other SRCTs) is diagnostic of ES. In difficult cases, 
cytogenetic analysis of EWSR1 by FISH or RT-PCR 
is needed for diagnosis.
Rhabdomyosarcoma
Rhabdomyosarcomas (RMSs) are the most common 
malignant soft tissue tumours in children, and 
embryonal RMS is most common type, which 
commonly arises in the head and neck region with a 
minority of cases in the musculature of extremities. 
Histologically, embryonal RMS typically displays 
alternating areas of hyper and hypocellularity. The 
cells vary considerably in differentiation ranging 
from primitive and stellate to others having moderate 
eosinophilic cytoplasm and still others showing 
terminal differentiation with abundant eccentric 
eosinophilic cytoplasm and cross-striations. The 
hypocellular areas contain myxoid stroma.
Clinical behavior and treatment varies for subtypes 
of RMS, so subclassification becomes just as critical 
Figure 1: Conventional Ewing Sarcoma  
showing uniform cells with round, regular nuclei 
containing finely dispersed chromatin and scant clear 
to slightly eosinophilic cytoplasm. (original 
magnification 400x).
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as diagnosis. Presence of anaplasia in embryonal 
RMS should be mentioned in histopathology report 
as it is associated with aggressive behavior. The 
diagnosis of RMS is made on morphology coupled 
with muscle markers desmin, myogenin and Myo 
D1.
Poorly Differentiated Synovial Sarcoma
Synovial sarcoma (SS) is a relatively common 
soft tissue sarcoma that most frequently occurs 
in extremities of adolescents and young adults 
with a peak incidence between 10 and 35 years. 
The three histologic types of SS are monophasic, 
biphasic and poorly differentiated. Poorly 
differentiated synovial sarcoma (PDSS) tends 
to occur more proximally than classical SS, and 
is composed of sheets of rounded or ovoid cells 
with increased mitotic activity, focal necrosis, and 
high proliferation index (Ki67), and resembles 
small round cell tumors, such as ES or lymphoma. 
PDSS shares a similar immunophenotype to 
classic SS such as EMA, Cytokeratin AE1/AE3, 
as well as CK7 and CK19. Almost all cases show 
nuclear expression of TLE1, a very sensitive but 
not specific marker for SS. Variable number of 
tumours express CD99, thus causing confusion to 
discriminate from ES. In those cases, molecular 
analysis of specific chromosomal translocation 
t(X;18)(p11,q11) by FISH or RT-PCR helps in 
arriving a correct diagnosis as treatment is entirely 
different for both tumours.
Mesenchymal Chondrosarcoma
Mesenchymal chondrosarcoma (MC) is a high 
grade sarcoma which mainly affects young adults 
and teenagers. Two thirds of cases involve bones 
especially ribs and jaw bones and one third of cases 
occur in soft tissues adjacent to the craniospinal axis 
including paraspinal musculature.  Histologically, 
MC is characterized by primitive small round cells 
arranged in sheets, vague nests or both, often in a 
hemangiopericytoma-like vasculature. These cells 
usually show an abrupt transition to single or lobules 
of well-differentiated hyaline cartilage.
The differential diagnosis includes other SRCTs such 
as atypical ES, and lymphoma, particularly when 
matrix component is not evident because of sampling 
error. Hematopoietic immunostains will rule out 
Figure 2: An embryonal rhabdomyosarcoma 
contains rhabdomyoblasts with central or eccentric 
nuclei and prominent, brightly eosinophilic 
cytoplasm (hematoxylin and eosin, original 
magnification x40).
Figure 3: Poorly differentiated synovial sarcoma. 
Note the predominantly round cell cytomorphology 
and transition from spindle cells.
Figure 4: The small blue cell portion of mesenchymal chondrosarcoma 
resembling other types of SRCTs, in particular atypical ES. A diagnosis 
can be made by finding areas containing the low-grade chondrosarcoma 
component.
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Small Cell Osteosarcoma
Small cell osteosarcoma is a rare histologic subtype 
of osteosarcoma composed of small cells simulating 
the appearance of ES or lymphoma. However, 
tumour cells produce osteoid or bony matrix, at 
least focally. The distinction between ES, especially 
atypical ES, and a small cell osteosarcoma can 
be difficult because of overlapping histologic and 
radiologic features.
Some Ewing sarcomas show fibrinous deposits 
among tumor cells, whereas the osteoid in small 
cell osteosarcoma is mineralized. Ancillary 
studies play an important role in cases in which 
osteoid production is questionable. Hematopoietic 
immunostains will distinguish lymphoma from small 
cell osteosarcoma. Small cell osteosarcoma can be 
immunoreactive with CD99, so it is not a useful 
stain in ruling out Ewing sarcoma. FLI-1is a better 
marker because most Ewing sarcomas are positive 
but small cell osteosarcomas are negative. Small cell 
osteosarcoma is an extremely uncommon tumor with 
a poor prognosis.
Neuroblastoma
Neuroblastoma are malignant childhood tumours 
derived from primordial neural crest cells. 
Neuroblastoma is the third most common childhood 
malignant tumor, after hematolymphoid and central 
nervous system neoplasms, but the most common 
solid tumor of infancy. Patients with metastatic 
neuroblastoma to bone are almost always younger 
than age five years. A chest and abdominal CT scan 
usually detects the primary site in cases where the 
lymphoma. Potential overlap with ES is exacerbated 
by the fact that >90 per cent of MCs show 
strong diffuse membranous positivity for CD99. 
Alternatively, FLI-1 has been shown to be positive 
in 75 per cent of ES and MC is negative. SOX9 is 
a useful marker for MC. The stromal component 
of small cell osteosarcoma may resemble MC. 
Moreover, small cell osteosarcoma also can show 
positivity with CD99. Careful attention paid to the 
type of matrix production-osteoid in osteosarcoma 
and cartilage in MC- is the best way to make the 
distinction. Sometimes this requires additional tissue.
Desmoplastic Small Round Cell Tumour
Desmoplastic small round cell tumour (DSRCT) 
is an aggressive small round cell neoplasm that 
predominantly affects children, adolescents, and 
young adults, with a male preponderance. The 
tumor characteristically occurs in the abdomen or 
pelvis, often with widespread serosal involvement. 
DSRCTs almost always consist of small nests of 
uniform round cells with hyperchromatic nuclei with 
inconspicuous nucleoli and scant cytoplasm set in a 
highly vascular, desmoplastic stroma. 
DSRCT is of uncertain histogenesis, but it shows 
polyphenotypic differentiation, displaying immune 
reactivity for epithelial (cytokeratin, EMA and 
BerEP4), muscle (desmin), and neural (NSE, 
synaptophysin). Desmin staining is usually dot-like, 
but muscle specific markers myogenin and MyoD1 
are negative. DSRCTs are highly aggressive, with 
more than 90% of patients dying from tumour 
progression within just a few years.
Classic appearance, with sharply demarcated nests 
of small round cells within a desmoplastic stroma 
containing spindle-shaped myofibroblasts embedded 
in a matrix of loose or myxoid extracellular material 
and collagen.
Figure 5: Desmoplastic Small Round Cell Tumour. 
Figure 6: The neoplastic cells in small cell osteosarcoma are small, 
round, and only occasionally spindle-shaped. The lacelike pattern of 
osteoid production differs from reactive bone sometimes seen in other 
types of SRCTs of bone.
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initial diagnosis is made or suggested via a bone 
biopsy. 
Melanotic Neuroectodermal Tumour of Infancy 
(Retinal Anlage Tumour)
Melanotic neuroectodermal tumour of infancy is a 
rare tumour usually present in the first year of life 
with a moderate predominance in boys. More than 90 
per cent of cases arise in the head and neck region, 
with an overwhelming predilection for the maxilla. 
The tumour has characteristic two principal cellular 
components: small basophilic neuroblast-like cells, 
often set in a fibrillary matrix, and larger epithelioid, 
eosinophlic cells with vesicular nuclei and containing 
variable amounts of melanin pigment. The latter cells 
are arranged in alveolar or pseudoalveolar structures 
set in a dense fibroblastic stroma. 
Immunohistochemically, both cell types stain 
positively for NSE and synaptophysin; in addition 
the larger cells show consistent immunopositivity for 
both cytokeratin and HMB-45, in parallel with the 
findings in pigmented retinal epithelium. 
B-Lymphoblastic Leukemia/Lymphoblastic 
Lymphoma (B-ALL/LBL)
B-Acute Lymphoblastic leukemia/lymphomas 
occur primarily in children.  Bone marrow is nearly 
always involved and peripheral blood is also usually 
involved.   The most frequent extramedullary 
sites to be involved by B-LBL include skin, 
soft tissue, lymph node and bone.  The clinical 
presentation is related to pancytopenia secondary to 
involvement of bone marrow. Lymphadenopathy and 
hepatosplenomegaly are also common.  The involved 
site is usually composed of sheets of small to 
intermediate sized monotonous lymphoblasts which 
have indented or convoluted nuclei and inconspicous 
to prominent nucleoli.  On immunohistochemistry, 
the lymphoblasts of B-ALL/LBL show positive 
expression for B-cell markers (PAX-5, cC79a, CD19, 
CD 24 and cCD22).  Of all these markers, PAX-5 is 
considered as the most sensitive and specific marker 
to demonstrate B-cell lineage.  The lymphoblasts 
are also positive for CD10 and TdT and negative for 
surface immunoglobulin (Ig).  Expression of CD20, 
CD45 and CD34 is variable.  There can be aberrant 
expression of myeloid-associated antigens CD13 and 
CD33 but Myeloperoxidase (MPO) will be negative.  
B-ALL with t(9;22)(q34;q11.2), t(v;11q23) and 
hypodiploidy are associated with poor prognosis.  
B-ALL with (12;21)(p13;q22) and hyperdiploidy 
are associated with favorable prognosis. Ages of 
less than one year and more than 10 years, high 
white blood cell count, presence of minimal residual 
disease after therapy and CNS disease at the time 
of diagnosis are associated with adverse outcome.  
B-ALL/LBL has a better prognosis in children than 
in adults.  
Figure 7: B-ALL/LBL A. The neoplastic cells are dyscohesive, are fairly 
uniform, have hyperchromatic nuclei, inconspicuous nucleoli and scant 
cytoplasm.  The B-lymphoblasts show characteristic positive expression 
for TdT (B) and PAX 5 (C) immunostains. (original magnification 40x).
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The most common cause of anaemia in young 
infants is “physiologic anaemia”, which occurs 
at approximately six to nine weeks of age. 
Erythropoiesis decreases dramatically after birth 
as a result of increased tissue oxygenation and a 
reduced production of erythropoietin. In healthy term 
infants, hemoglobin (Hb) levels are high (>14 g/dL) 
at birth and then rapidly decline, reaching a nadir of 
approximately 11 g/dL at six to nine weeks of age, 
which is called “physiologic anaemia of infancy”.
Pathologic anaemia in newborns and young infants 
is distinguished from physiologic 
anaemia by any of the following.
l Anaemia (Hb <13.5 g/dL) within 
 the first month of life
l Anaemia with lower Hb level than 
 is typically seen with physiologic 
 anaemia (ie, <9 g/dL)
l Signs of hemolysis (eg, jaundice, 
 scleral icterus, or dark urine) or 
 symptoms of anaemia (eg, 
 irritability or poor feeding)
Common causes of pathologic anaemia 
in newborns include blood loss, 
immune hemolytic disease (ie, Rh 
or ABO incompatibility), congenital 
infection, twin-twin transfusion, and 
congenital hemolytic anaemia (eg, 
hereditary spherocytosis, glucose-6-
phosphate dehydrogenase [G6PD] 
deficiency). Hyperbilirubinemia in the 
newborn period suggests a hemolytic 
etiology; microcytosis at birth suggests 
chronic intrauterine blood loss or 
thalassemia.
Thorough history taking and physical 
examination are the primary steps 
in identifying the condition and 
establishing an etiology, but further 
investigations in the form of laboratory 
testing are often required to differentiate 
the many possible causes.
Laboratory investigations can aid in 
determining the underlying cause of 
neonatal anaemia; however, it is often difficult to 
decide which tests to obtain and how to interpret 
the results. It is therefore beneficial to proceed 
with investigation in a stepwise manner to avoid 
unnecessary testing that will delay and confuse 
proper diagnosis. The following algorithm can be 
easily followed to help in establishing a diagnosis of 
anaemia and its underlying etiology. 
Anemia
(HGB <13.5 g/
dL)
Reticulocyte
Count
Increased
reticulocytes
Decreased
reticulocytes
· Anemia of prematurity
· Anemia after Rh incompatibility
· Diamond-Blackfan Anemia
· Drug induced RBC Suppression
DAT DAT positive · Rh or ABO incompatibility
· Other blood group incompatibility
DAT Negative
MCV Low MCV
· Chronic intrauterine blood loss:
· Twin / twin
· Fetomaternal /
· Abruption placentae
· Alpha or Beta Thalassemia
Normal or High
MCV
Peripheral
Smear Abnormal
Normal
Hemolysis ?
Congenital RBC enzyme defects
· G6PD deficiency
· PK deficiency
· Hexokinase deficiency
· Others
Hemolysis
Present
Infections
· Bacterial
· Viral (CMV, HSV, Rubella, Enterovirus, Adenovirus)
· Toxoplasmosis
· Fungal
Other
· Galactosemia
· Hypothyroidism
· Hereditary Spherocytosis
· Hereditary Elliptocytosis
· Hereditary stomatocytosis
· Pyknocytosis
· DIC
· Microangiopathy hemolytic anemias
· Hemoglobinopathies
No Hemolysis Blood Loss
HGB: hemoglobin; RBC: red blood cell; DAT: direct antiglobulin test; MCV: mean 
corpuscular volume; DIC: disseminated intravascular coagulation; PK: pyruvate 
kinase; G6PD: glucose-6-phosphate dehydrogenase; CMV: cytomegalovirus; 
HSV: herpes simplex virus.
Source: Gallagher PG. The neonatal erythrocyte and its disorders. In: Nathan and Oski’s 
Hematology and Oncology of Infancy and Childhood, 8th Ed, Orkin SH, Fisher DE, Look AT, 
et al (Eds), WB Saunders, Philadelphia 2015. p.52.
Diagnostic approach to anaemia in the newborn
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Evaluation of Inborn Errors of Metabolism 
(IEM) In a Nutshell
Dr Noreen Sherazi
Chemical Pathology 
Inborn Errors of Metabolism (IEM) are single gene 
defects, responsible for the abnormalities in the 
synthesis or catabolism of proteins, carbohydrates 
or fats by way of defective enzymes or transport 
proteins, resulting in a block of metabolic pathway. 
They are mostly inherited in autosomal recessive 
pattern and parent consanguinity increases chance of 
inheritance in offspring. IEM was first described by 
Garrod at the beginning of the 20th century; several 
hundred new disorders have now been defined, as 
new robust biochemical and molecular diagnostic 
tools became available.
IEM can affect any organ system and usually affect 
multiple organ systems. Manifestations vary from 
those of acute life threatening disease to sub-acute 
progressive degenerative disorders. For evaluating 
an IEM it is essential to consider following five 
important aspects i.e.:
l Detailed Clinical History: Proper history from 
 parents has a role in suspecting IEM (Table 1) as 
 detailed history is necessary for further diagnosis.
l Physical examination: To look for dermatitis, 
 alopecia, facial dysmorphia, cataract etc.
l Metabolic screening tests: These include 
 complete blood count, Urine D/R, plasma glucose, 
 plasma ammonia, plasma lactic acid, arterial blood 
 gases and electrolytes
l Follow up/Selective screening: The test is 
 performed on the basis of clinical context which 
 includes quantitation of amino acids, organic 
 acids, carbohydrate and other metabolites, Long 
 chain fatty acids, MPS separation and speciation. 
 Clinical laboratory AKUH started first local 
 diagnostic biochemical genetics laboratory in the 
 country and offering testing facility for screening 
 and diagnosis of IEMs Table 2.
l Definitive diagnostic tests: To confirm the 
 disorder detected, specific enzyme assays in 
 leucocytes, plasma/serum or red cells, 
 immunoassays and DNA/ mutation based analysis 
 will be tested. 
The role of follow-up testing or selective screening 
in narrowing the differential diagnosis in suspected 
IEM individuals is crucial as per National Academy 
of Clinical Biochemistry. (NACB) practice 
guidelines Table 3.
Prenatal Factors
Consanguinity
Previous sibling 
death
Antenatal Factors 
CNS anomalies
Hydrops fetalis
Echogenic kidneys
Stippling epiphyses
Postnatal Factors
Healthy neonate at 
birth became sick 
after few hours or 
days of life
Refusal to feed
Sepsis, lethargy, 
hypotonia
Ketosis, hypoglycemia
Dysmorphic features
Table 1: Risk Factors in Suspected IEM Disorders
Metabolic Screening 
Panel
 CBC, 
 Urine D/R 
 Blood Glucose
 Plasma Ammonia 
 Plasma Lactic Acid 
 Arterial Blood Gases
 Electrolytes
Selective or Follow up 
Testing Services
 Plasma/ Urine/ CSF 
 quantification of Amino Acids
 Qualitative Urine Organic acids
 Urine Succinylacetone
 MSUD Profile
Table 2:  Initial and Follow Up Testing Facility at Clinical 
Laboratory AKUH for IEM Disorders
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Table 3: Common Disease-Specific Follow-Up Testing Recommendations by NACB
Phenylketonuria
Tyrosinemia Type 1
Tyrosinemia Type 2
Maple Syrup Urine Disease
Homocytsinuria
Argininosuccinic acidemia
Methylmalonic acidemia
Isovaleric Acidemia
Propionic acidemia
Multiple Carboxylase 
Deficiency
Glutaric Aciduria Type 1
Glutaric Aciduria Type 2
Plasma Amino acids
Urine organic acids
Plasma amino acids
Plasma amino acids
Immunoassay
Plasma/Urine amino acids
Urine Organic Acids
Plasma/Urine amino acids
Urine organic acids
Urine organic acids
Urine organic acids
Urine organic 
Acids +  Plasma  
Acylcarnitine*
Urine Organic acids
Urine Organic acids
Phenylalanine
Succinylacetone
Tyrosine >1000 μM  on 
presentation
Isoleucine + valine + leucine + 
alloisoleucine
Homocysteine
Methionine, Homocystine
Methylmalonic acid
Argininosuccinate, Citrulline
Methylmalonic, 3-OH 
propionic, tiglylglycine, 
methylcitrate
3-OH isovaleric acid, isovaleryl 
glycine
3-OH propionic, tiglylglycine, 
methylcitrate, propionylglycine
3-OH propionic, 3 OH isovale-
ric, tiglylglycine 
methylcitrate, 3-MCC 
(glycine), lactate
Glutaric, 3-OH Glutaric
Glutaric, 2-OH Glutaric, adipic, 
suberic, sebacic  ethylmalonic, 
3-OH isovaleric, isobutyric
Urine Pterin*, Dihydropteridine 
reductase activity*
No additional testing
No additional testing
Folate/Vitamin B12 status 
should be investigated
Disorders of cobalamin 
metabolism should also be
considered
Methylmalonic CoA mutase 
activity*
No additional testing
Complementation analysis, 
B12 studies*
No additional testing
B12 studies*
Biotinidase activity,
Isolated carboxylase activities 
+ biotin*
No additional testing
Follow-up 
Analyses
Follow-up Markers Additional Testing
Amino Acids Disorders
Organic Acid Disorders
*Not available at Clinical Laboratories AKUH
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Clinical Utility of Immature Platelet Fraction 
– An advanced Parameter in Laboratory 
Hematology
Dr Sidra Asad Ali and Dr Muhammad Shariq Shaikh
Haematology
Platelets, first described by a German anatomist as 
‘spherules’ nearly a century ago, are multifunctional 
anucleated cells that play a vital role in hemostasis. 
They are cytoplasmic fragments of megakaryocytes 
with dimensions of approximately 2.0–4.0 by 0.5 
μm and a mean volume of 7–11 fl. Platelets act as 
an initial hemostatic wave through their adhesive 
and cohesive properties leading to the formation 
of platelet plug with subsequent activation of 
coagulation pathways in order to consolidate the 
primary hemostatic plug.  Average platelet count 
ranges between 150 and 410 × 109/L of blood. 
However, in patients with thrombocytopenia, 
count alone does not provide precise assessment 
of bleeding risk and platelet production from 
bone marrow. Analogous to red cell reticulocytes, 
immature platelets or reticulated platelets are young 
platelets that circulate in the peripheral blood and 
provide functional status of platelet production by 
bone marrow.
Owing to their high ribonucleic acid (RNA) content, 
immature platelets can be differentiated from their 
mature counterparts. This was first demonstrated 
by Kienast and Schmitz in 1990 utilizing flow 
cytometry. Since then, several modifications have 
been developed utilizing multi-color flow cytometric 
analysis and different flouro-chromes providing 
simple, rapid and precise assessment of reticulated 
platelets. In modern automated hematology analyzers 
equipped with this sophisticated method, fluorescent 
dyes penetrate the cell membrane through a breach 
created by surfactant and label the RNA. It is 
reported as percentage of the total platelet count 
(%-IPF). The normal reference range for IPF ranges 
from 1.6-7.1 per cent in adults and 1.0-6.8 per cent in 
pediatric population. 
Since IPF provides status of bone marrow 
thrombopoiesis, it can be utilized for diagnosis 
and management of various disorders. 
Raised IPF levels are seen in conditions with 
high platelet turn over like disseminated 
intravascular coagulation (DIC), thrombotic 
thrombocytopenic purpura (TTP) / 
hemolytic uremic syndrome (HUS), immune 
thrombocytopenic purpura (ITP), blood loss 
and others.  Whereas, low levels are observed 
in individuals with bone marrow suppression 
such as aplastic anemia and other bone marrow 
failure syndromes, nutritional deficiencies and 
drug induced myelosuppression.
Besides its role in aiding the diagnosis of above 
disorders, IPF can be utilized to monitor the 
diseases process and to assess need of platelet 
transfusion. In disorders with high platelet turn 
over like ITP, initially high IPF values tend to 
decline as the disease responds to treatment. 
Similarly, low IPF values in drug induced 
myelosuppression and viral hemorrhagic fevers 
will return to normal range with improvement in 
disease process. Since IPF levels decline around 
24-48 hours before improvement in platelet 
counts, unnecessary platelet transfusion can be 
prevented in such conditions.
In conclusion, IPF is a unique, rapid, non-
invasive and in-expensive tool to assess bone 
marrow thrombopoietic activity and is available 
24/7. All these properties are highly desirable 
specifically in paediatric settings where bone 
marrow examination may not be always practical. 
At AKUH clinical laboratories, state of the art 
fully automated hematology analyzers of Sysmex 
XE class, incorporate this sophisticated method 
of IPF measurement. This test will soon be started 
andenable us to provide highly reliable and 
important information about thrombopoietic activity 
on a single blood sample.
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Multiplex Ligation-Dependent Probe Amplification 
(MLPA) to Screen for Mutations Leading 
to Duchenne Muscular Dystrophy (DMD)
Dr. Zeeshan A Ahmed, Dr  Asghar Nasir and Sheeba Parveen
Molecular Pathology 
Duchenne Muscular Dystrophy (DMD) is an 
inherited X-linked recessive genetic disorder. 
Individuals who inherit it have a defective gene 
related to a muscular protein called dystrophin. This 
protein keeps muscle cells intact, and its absence 
causes rapid muscular deterioration. DMD is a fatal 
condition and most sufferers pass away during their 
twenties. In the later stages of the disease, sufferers 
are completely disabled and require full-time care. 
The condition is degenerative. DMD symptoms 
may begin to appear between age two and six and 
include: difficulty walking or loss of ability to walk, 
enlarged calves, learning disabilities, lack of motor 
skills development, fatigue and rapidly worsening 
weakness in the legs, pelvis, arms, and neck. 
Dystrophin, the largest known human gene (2.4 Mb) 
is located on the short (p) arm of the X chromosome 
at position 21.2. The DMD gene is located from base 
pair 31,119,219 to base pair 33,339,609 on the X 
chromosome. Mutations in the dystrophin gene alter 
the structure or function of dystrophin or prevent 
any functional dystrophin from being produced. 
This protein is located primarily in muscles used for 
movement (skeletal muscles) and in heart (cardiac) 
muscle. In skeletal and cardiac muscles, dystrophin 
is part of a group of proteins that work to strengthen 
muscle fibers and protect them from injury as 
muscles contract and relax. Muscle cells without 
enough of this protein become damaged and the 
damaged fibers weaken and die over time, leading to 
the muscle weakness.
Molecular Diagnostic approach to Screen for 
Mutations DMD 
In suspected DMD patients, an initial investigation 
involves studying the levels of creatine kinase (CK). 
Normal serum CK levels at presentation excludes 
DMD; however an elevated serum CK level obviates 
the need for a muscle biopsy with an assay for 
dystrophin protein.  Molecular testing is useful to 
confirm a clinical diagnosis in affected patients. 
For DMD it is recommend to initially screening for 
deletions and duplications, followed by a screen for 
point mutations if the clinical diagnosis is certain but 
a deletion/duplication has not been found, See Figure 
1. Since whole exon deletions are the predominant 
type of mutation in the DMD gene (65 per cent), an 
initial screen which detects the majority of deletions 
should be the minimum level of diagnostic test 
offered. Currently the most widely used methods 
for screening are Multiplex PCR and Multiplex 
Ligation-Dependent Probe Amplification (MLPA).
Screening of DMD by MLPA (Multiplex Ligation-
Dependent Probe Amplification)
The principle of Multiplex Ligation-dependent Probe 
Amplification (MLPA) is based on the amplification 
(by use of a single PCR primer pair) of multiple 
probes, each of which detecting a specific DNA 
sequence of approximately 60 nucleotide in length. 
MLPA reagents together with a wide range of MLPA 
probe mixes can be used to detect deletions and 
duplications in a DNA sample.
Figure 2A shows a typical MLPA reaction. After 
denaturation of the sample DNA, a mixture of MLPA 
probes is added to the sample. Each MLPA probe 
consists of two oligonucleotides that must hybridise 
to immediately adjacent target sequences in order 
to be ligated into a single probe. Each probe in an 
MLPA probemix has a unique amplicon length, 
typically ranging between 130-500 nucleotides. 
During the subsequent PCR reaction, all ligated 
probes are amplified simultaneously using the same 
PCR primer pair. One PCR primer is fluorescently 
labeled, enabling the amplification products to be 
visualized during fragment separation. This is done 
on a capillary electrophoresis instrument, yielding 
a specific electropherogram. The relative height 
of each individual probe peak, as compared to the 
relative probe peak height in various reference 
DNA samples, reflects the relative copy number of 
the corresponding target sequence in the sample. 
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A deletion of one or more target sequence thus 
becomes apparent as a relative decrease in peak 
height while an increase in relative peak height 
reflects amplification. Figure 2B shows MLPA 
results with probe P034 in normal control sample 
(top panel) compared with a case of deletion (middle 
panel) and a case of duplication (bottom panel). 
 
DMD can be caused by deletions, duplications 
or point mutations in the DMD gene that 
encodes the protein dystrophin, however to what 
extent DMD manifests depends on whether the 
translational reading frame is lost or maintained. 
Partial gene deletions or duplications in the DMD 
gene account for as much as ~65% of cases of 
these dystrophies. This extremely high percentage 
may be due to the nature of the protein and the 
gene’s extreme length (> 2.2 Mb). The MLPA 
based DMD probemix contains probes for each of 
the exons of the DMD gene (79 exons) on Xp21.2 
chromosome. Performing MLPA reactions is thus 
sufficient to investigate the copy number of all 
exons. 
In conclusion, MLPA offers a more extensive 
screening than many other methods used in DMD 
analysis as it makes possible to find deletions/
duplications that were previously overlooked.
Figure 1: Molecular Diagnostic approach to Screen for DMD Gene Mutation
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Figure 2: MLPA reaction (A) results showing deletion and duplication (B). 
2A. Reproduced from MRC-Holland - Products - Details - P034 DMD mix 1
2B. Reproduced from Sakthivel Murugan S.M., et al 2013
An Update on Blood Lead Levels in Children
Dr Hafsa Majid 
Chemical Pathology
Childhood lead poisoning is one of the most 
common and entirely preventable diseases of 
toxic environmental origin. It remains a problem 
of enormous importance for child health and 
development worldwide and lead poisoning 
accounts for about 0.6 per cent of the global burden 
of disease. The condition is worse especially in 
developing countries, as due to limited available 
resources there focus remains on infectious 
diseases. Lead plays no essential role in the human 
body and is ubiquitous in the environment leading 
to clinical and subclinical toxicity primarily through 
ingestion and inhalation.
The American Academy of Pediatrics and Centers for 
Disease Control and Prevention (CDC) recommend 
that blood lead screening be done of  all children at 
the ages of approximately one and two years. The 
levels are evaluated according to cutoffs defined 
by CDC, which are now updated after every four 
years based on recent evidence of lead related 
health hazards and United States NHANES surveys 
reporting lead exposure in children. Recently 
recommended CDC action lead level of children for 
the period of 2012-2016 are <5ug/dl. But mounting 
evidence now is showing that blood lead levels 
(BLLs) that were considered previously to be safe 
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can compromise health and injure multiple organs, 
even in the absence of overt symptoms. Recent 
research indicates that lead is associated with 
neurobehavioural damage at blood levels of 5 µg/dl 
and even lower. So there appears to be no threshold 
level below which lead causes no injury to the 
developing human brain.
The gravest consequence of low level or subclinical 
lead toxicity in childhood is damage to the 
developing brain and nervous system and as the 
human brain has little capacity for repair, so the 
hazardous effects are untreatable and irreversible. 
The immune, reproductive and cardiovascular 
systems are also adversely affected by relatively 
low levels of exposure to lead. The Joint FAO/WHO 
Expert Committee on Food Additives reevaluated 
lead in June, 2010 and withdrew the provisional 
tolerable weekly intake guideline value on the 
grounds that it was inadequate to protect against IQ 
loss. Researchers are proposing even lower action 
lead levels then recommended by CDC and in few 
countries government agencies have already lowered 
their BLL cutoffs as well as recommendations 
regarding selective screening to mandatory screening 
for all children, for example Germany; action BLL 
for children are now lowered to <3.5ug/dl. 
Avoidance of lead exposure remains the primary 
preventive strategy for reducing adverse health 
effects of lead poisoning. So approaches to reduce 
lead exposure should by adopted, on local as well as 
public level. Exposure sources should be identified 
and eliminated or controlled to reduce this trace 
metal’s environmental toxicity. Along with it action 
BLL should be redefined for our population and 
awareness should be raised regarding this issue at 
all levels; among public health officials, healthcare 
providers as well as general public. 
Blood Lead Levels Testing at AKUH Clinical 
Laboratory
Blood lead levels are analyzed to detect and confirm 
exposure to lead. It may also be ordered to monitor 
the effectiveness of treatment and to confirm that 
lead levels are decreasing over time. At AKUH 
Clinical Laboratory lead is analysed by Graphite 
Furnace Atomic Absorption Spectrometry. For 
analysis 4 cc whole blood in Lithium Heparin tube 
is needed. Please note the sample should not be 
centrifuged or plasma must not be separated as whole 
blood is required.
1. Hypophosphatemic rickets or X linked 
 Hypophosphatemic (XLH) rickets, usually 
 presents with typical signs of rickets in young 
 children.
2. To confirm Hypophosphatemic rickets, as it is 
 accompanied by hypophosphatemia and low 
 TmP/GFR hence TmP/GFR calculation will 
 confirm his suspicion. 
3. The TmP/GFR estimate the ratio of phosphorus 
 tubule maximum (TmP) to glomerular filtration 
 rate (GFR), to evaluate renal phosphate transport. 
 Ratio is calculated by following formula: 
 Tmp/GFR= SPO4 – [(UPO4×SCr)/ UCr]
4. The XLH rickets is caused by various mutations 
 in the PHEX gene (Xp22.1) and is transmitted as 
 an X-linked dominant trait with complete 
 penetrance, but variable expressivity. PHEX 
 encodes an endopeptidase expressed 
 predominantly in bone and teeth that regulates 
 fibroblast growth factor 23 (FGF-23) synthesis. 
 PHEX mutations lead to increased circulating 
 levels of FGF-23, a phosphate-regulating 
 hormone (phosphatonin), that leads to reduced 
 renal phosphate reabsorption and consequently 
 abnormal bone mineralization. Eventually there 
 is decreased proximal renal tubular resorption 
 of phosphate, resulting in renal phosphate 
 wasting and hypophosphatemia due to 
 these circulating phosphatonins. The principle 
 phosphatonin in hereditary hypophosphatemic 
 rickets is FGF-23. 
5. 1,25-dihydroxyvitamin D should be tested. 
 Patients with XLH have normal or low 
 serum levels of 1,25-dihydroxyvitamin D3 
 (also known as calcitriol, the active form of 
 vitamin D), despite having hypophosphatemia, 
 which is a known stimulus of 25-hydroxyvitamin 
 D-1-alpha-hydroxylase activity.
Quiz Answers: 
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Meeting Report: “Les Confluences” The Society 
for the Study of Inborn errors of Metabolism 
(SSIEM) Annual Symposium 2015 in Lyon, France 
Dr Noreen Sherazi
Chemical Pathologist
SSIEM is aimed to foster the study of inherited 
metabolic disorders and related topics. It promotes 
exchange of ideas between professional workers in 
different disciplines who are interested in inherited 
metabolic disease. The origin of SSIEM may be 
traced to an informal meeting held in England at the 
Manchester Royal Infirmary in 1962 when an 
enthusiastic group of biochemists and pediatricians 
met to discuss phenylketonuria. 
The annual symposium of SSIEM 2015 was held in 
Lyon from 1st till 4th September at Lyon Convention 
Centre which was located at the Cité Internationale 
de Lyon between the Parc de la Tête d’Or and the 
Rhône River. The theme of the symposium was taken 
from the word “Les Confluences”:  where Rhône 
and Saone rivers join in French. In SSIEM, all health 
professionals work together and when basic research 
helps clinicians. This symposium was attended by 
two Chemical Pathologist Dr. Aysha Habib Khan 
and Dr. Noreen Sherazi and Metabolic Physician Dr. 
Bushra Afroze from Aga Khan University, Karachi. 
Abstract regarding frequency of selective screening 
of organic acidurias and amino acidopathies was 
selected for poster presentation and two other 
abstracts were published in abstract book related to 
quality control and proficiency testing of biochemical 
genetics laboratory, AKU. 
The day one commenced with an attractive scientific 
program including informative ERNDIM meeting 
regarding critical errors in proficiency testing 
followed by Industry Sponsored Symposia on PKU, 
lunch and poster walk. There was opening ceremony 
and plenary session on “confluence of research and 
inborn errors” followed by a refreshing welcome 
reception towards the end of a hectic day. 
Day two started with the parallel session on 
Organic acidurias/Urea cycle disorders, Amino 
acids disorders and Mitochondrial disorders where 
researchers from France, Switzerland and Italy 
presented their work on various topics including 
MMA, propionic acidurias, GA type one, OTC 
deficiency and mutations causing 3-methylglutaconic 
acidurias etc. A very informative plenary session 
on “Antenatal manifestations of IEMs discussed 
fetopathological investigations, diagnostic workup 
and imaging findings of IEMs in antenatal period 
after the lunch. 
Day three had various plenary sessions on riboflavin 
and fatty acid oxidation, neurometabolic disorders, 
vitamins and cofactors and disorders of lysosomal 
storage. One hour industry sponsored session on 
“Metabolic decompensation in PA and MMA” was 
very practical and interactive session. Last day was 
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also concluded with plenary sessions, hot topics 
and late breaking news, Garrod award lecture on 
transcobalamin deficiency and closing remarks with 
SSIEM Rome 2016 presentation and awards.
Over all the sessions were clinical oriented and 
research based but as a pathologist these sessions 
were beneficial in gaining clinical perspective in the 
area of IEM as it will enhance the understanding 
of inherited disorders and quality of diagnostic 
reporting along with the future developments in the 
field of IEM.
Lyon is internationally known for its gastronomy, 
which was shared with us during the networking 
afternoon on day three where we had the opportunity 
to discover different aspects of the Capitale des 
Gaules, a UNESCO World Heritage site since 1998. 
It was great honor to present the biochemical 
genetics laboratory two years data on selective 
screening of organic acidurias and amino 
acidopathies from AKUH at the international 
symposium of SSIEM 2015. This was first local data 
of IEM diagnosed with locally available expertise in 
Pakistan. Not only abstract was selected for poster 
presentation but they have also awarded travel 
scholarship to Dr. Noreen Sherazi in order to attend 
the annual symposium 2015. This project was the 
collaborated efforts of Faculty of Section of Clinical 
Chemistry, Department of Pathology and Laboratory 
Medicine, Technical staff of Biochemical genetics 
unit and Metabolic Physician, Dr. Bushra Afroze 
from Pediatrics Department AKUH.
hospitals.aku.edu/Karachi/clinical-laboratories
